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3,4-Methylenedioxypyrovalerone (MDPV) acts as a dopamine transporter blocker and 
exerts powerful psychostimulant effects. In this study we aimed to investigate the 
bidirectional cross-sensitization between MDPV and cocaine, as well as to evaluate 
the role of the BDNF-TrkB signaling pathway in the development of locomotor 
sensitization to both drugs.  
Mice were treated with MDPV (1.5 mg/kg) or cocaine (10 or 15 mg/kg) once daily for 5 
days. After withdrawal (10 days), animals were challenged with cocaine (8 mg/kg) or 
MDPV (1 mg/kg). For biochemical determinations, MDPV (1.5 mg/kg) or cocaine (15 
mg/kg) were administered acutely or repeatedly, and BDNF, D3R and G9a 
transcription levels as well as pro- and mature BDNF protein levels were determined. 
Our results demonstrate that repeated administration of MDPV or cocaine sensitizes 
to cocaine and MDPV locomotor effects. After an acute or a repeated exposure to 
MDPV, cortical mRNA BDNF levels were increased, while a decrease in mBDNF 
protein levels in the nucleus accumbens 2h after repeated exposure was evidenced. 
Interestingly, such decline was involved in the development of locomotor sensitization, 
thus the pretreatment with 7,8-dihydroxyflavone (10 mg/kg), a TrkB agonist, blocked 
the development of sensitization to MDPV but not to cocaine, for which no changes in 
the BDNF-TrkB signaling pathway were observed at early withdrawal. 
In conclusion, a bidirectional cross-sensitization between MDPV and cocaine was 
evidenced. Our findings suggest that decreased BDNF-TrkB signaling has an 
important role in the behavioral sensitization to MDPV, pointing TrkB modulation as a 
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1. INTRODUCTION 
During the last decade the illicit drug market has changed considerably due to the 
emergence of New Psychoactive Substances which include synthetic cathinones. The 
popularity of cathinones as recreational drugs has been increasing since they broke 
into the drug market, so that they are used as substitutes for other classical 
psychostimulants such as cocaine or ecstasy. 
3,4-methylenedioxipyrovalerone (MDPV) is one of the most popular synthetic 
cathinones and one of the main ingredients of the so-called “bath salts” [1,2]. As many 
psychostimulants, MDPV produces some of its neurochemical effects by interacting 
with the transporters of monoamine neurotransmitters. In the same way as   cocaine, 
MDPV increases dopamine (DA) levels in the synaptic cleft by inhibiting its uptake. 
Animal studies indicate that MDPV is 10-50-fold more potent as a dopamine 
transporter (DAT) blocker than cocaine [3,4]. Moreover, it has also been demonstrated 
that MDPV exerts powerful psychostimulant, rewarding and reinforcing effects related 
to cocaine at one tenth-doses [5], pointing to a high abuse liability and thus a 
presumable upward consumption of this substance in the next years, probably favored 
by its affordable cost. Therefore, new findings about MDPV and its relationship with 
addiction are of special interest. The research on this topic becomes important 
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considering the potential health and social consequences associated with newly 
emerging molecular variants of this drug. 
Behavioral sensitization to psychostimulants is the process whereby repeated 
intermittent exposure to drugs results in a progressive and enduring increase in the 
motor stimulant response to the drug [6–10]. Furthermore, behavioral sensitization is 
a long-lasting phenomenon, shown to persist for at least one year after cessation of 
drug administration [11]. Hence, repeated drug exposure may induce dynamic 
changes in neural processes, which may influence susceptibility to drug abuse and 
relapse by increasing the reinforcing value of acute drug administration [9,12]. It is also 
known that the ventral tegmental area (VTA) is essential for the development of 
behavioral sensitization, whereas the nucleus accumbens (NAcc) seems to be 
necessary for its expression [13,14]  
There is convincing evidence that the brain-derived neurotrophic factor (BDNF) along 
with its specific receptor, tropomyosin receptor kinase B (TrkB), have a key role in the 
behavioral abnormalities observed in rodents after psychostimulant administration 
[15–17]. BDNF present in NAcc and dorsal striatum ischiefly , but not exclusively,  
supplied by anterograde axonal transport from cortical pyramidal neurons in frontal 
cortex [18–20]  
Research done over the last two decades, has reported BDNF to be involved in the 
long-term neuronal adaptations leading to functional modifications in the synapses 
associated with cocaine abuse and related behaviors [17,21,22]. Moreover, it is also 
involved in the behavioral abnormalities and neurotoxicity induced by 
methamphetamine consumption [23]. Hence, the BDNF-TrkB signaling may be a 
potential therapeutic target for treating drug addiction. 
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Transcription of the BDNF gene is under control of not only transcriptional factors but 
also of epigenetic mechanisms including chromatin remodeling and DNA methylation 
[24]. G9a is a histone 3 lysine 9 (H3K9me2)-specific dimethyltransferase that acts as 
a negative regulator of BDNF signaling through TrkB [25]. It is also known that repeated 
exposure to cocaine induces long-lasting epigenetic changes in the brain, modifying 
the chromatin structure of DNA via histone acetylation, phosphorylation, and/or 
methylation [26,27]. For instance, Maze et al. [28] demonstrated that H3K9me2 is 
substantially reduced in the NAcc after chronic cocaine exposure due to decreased 
levels of G9a. In this sense, it has been identified an essential role for H3K9m3 and 
G9a in cocaine-induced structural and behavioral plasticity [28].  
At the same time BDNF, synthesized in either VTA neurons or neurons originating from 
the cortex, controls dopamine 3 receptor (D3R) expression [29]. Interestingly, 
hyperresponsiveness to drug-associated cues and context-dependent behavioral 
sensitization might be related to hypersensitive postsynaptic dopaminergic receptors. 
Among them, D3R seems to be a key target since it is highly expressed in the shell of 
NAcc, in which DA release is mainly triggered by drugs [30]. Furthermore, D3R 
expression controls behavioral sensitization and BDNF [29,31], which at the same time 
controls D3R expression and enhances the conditioned reward and locomotor activity 
induced by cocaine [32]. 
Drug-induced locomotor sensitization has been described for both cocaine and MDPV 
[33–36]. The fact that different addictive drugs produce the same effect implies that 
they may exert some of their effects through the same neural mechanisms. 
Furthermore, cross-sensitization between other addictive drugs has also been 
described [37,38]. For this reason, the present study aims to investigate for the first 
6 
 
time the bidirectional cross-sensitization between MDPV and cocaine, as well as to 
determine and compare the changes induced by either acute or chronic exposure to 
MDPV or cocaine on the transcription of plasticity genes in early abstinence. Thus, this 
work is mainly focused on the role of BDNF-TrkB signaling pathway in the development 
of behavioral sensitization to MDPV and cocaine, and also its target gene, d3r, and the 
regulator histone methyltransferase G9a.  
2. MATERIALS AND METHODS 
2.1. Animals 
Male adolescent (PND 41-44) Swiss CD-1 mice (Charles River, Spain) were used for 
all experiments due to its optimal sensitivity to the reinforcing and psychostimulant 
effects of cocaine (McKerchar et al., 2015). Animals were randomly assigned to an 
experimental group and housed six per cage in temperature-controlled conditions (22 
± 1 ºC) under a 12 h light/dark cycle and had ad libitum access to standard food and 
water. During the behavioral manipulations, researchers were not aware of the 
treatment that each animal had received. All the procedures adhered to the 
guidelines of the European Community Council (2010/62/EU) and ARRIVE and were 
approved by the Animal Ethics Committee of the University of Barcelona. All efforts 
were made to minimize animal suffering and to reduce the number of animals used. 
2.2. Materials 
Pure racemic MDPV · HCl was synthesized and characterized in our laboratory as 
described (Novellas et al., 2015). Cocaine was provided by the Spanish National 
Institute of Toxicology. MDPV and cocaine solutions for injection were prepared in 
0.9% NaCl (saline, pH=7.4) immediately before administration.  
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Both TrkB ligands 7,8-Dihydroxyflavone (7,8-DHF) and ANA-12 (N-[2-[[(Hexahydro-2-
oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide)  were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and were prepared as a micro-
suspension in phosphate-buffered saline containing 0.5% (w/v) carboxymethyl 
cellulose and 0.1% (v/v) Tween-80.  
Specific ELISA mBDNF and proBDNF Kits were purchased from Biosensis (Thebarton 
SA, Australia), the protease and phosphatase inhibitor cocktail from Abcam 
(Cambridge, UK) and the organic solvents ethanol, chloroform and isopropanol, from  
Scharlab (Barcelona, Spain) The rest of reagents were of analytical grade and 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
2.3. Drug administration protocol and experimental design 
For cross-sensitization experiments animals followed the administration regime 
depicted in Figure 1.  
A moderate dose of MDPV (1.5 mg/kg, s.c.) eliciting hyperlocomotion was chosen for 
this study. This dose, in mice, is equivalent to a dose of approximately 8 mg in humans 
[40,41] which is in the middle range of the doses most commonly used by consumers 
[42]. The doses of cocaine (10 and 15 mg/kg, i.p.) have been chosen on the basis that 
MDPV is at least 10-fold more potent than cocaine in vivo and in vitro [3–5,43]. No 
higher doses were used since those we selected predominantly induce locomotor 
activity (e.g., horizontal forward locomotion, even though some occasional licking were 
observed), whereas higher doses could produce non-ambulatory stereotypies, such as 
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head bobbing, sniffing or licking that could have interfered the analysis because of the 
competition between non-ambulatory behaviors and locomotor activity.  
The sensitization procedure consisted of three phases over 17 days: habituation, 
treatment and challenge. In the habituation phase (the two days prior treatment, days 
-1 and 0), mice were handled for 10 min, injected with saline (5 ml/kg) and immediately 
placed for 45 min in a black Plexiglass open field arena. After the habituation phase, 
mice were injected with saline (5 ml/kg), MDPV (1.5 mg/kg s.c.) or cocaine (10 mg/kg 
or 15 mg/kg i.p.) once daily for five consecutive days (days 1-5). Animals were placed 
in the open field arena immediately after each saline or drug injection and their 
horizontal locomotor activity (HLA) was recorded. Ten days after the final 
administration (day 15), all mice were challenged with cocaine (8 mg/kg i.p.) or MDPV 
(1 mg/kg s.c.) and their HLA was registered again. 
For biochemical determinations, acute and chronic exposure regimes were designed. 
In acute experiments, a single dose of saline (5 ml/kg), MDPV (1.5 mg/kg s.c.) or 
cocaine (15 mg/kg i.p.) were injected and animals were sacrificed 1h or 2h post-
administration for the subsequent study of different markers. The chronic 
administration protocol was the same as the one used for the cross-sensitization 
experiments (Figure 1) but sacrificing the animals 2h, 24h or 10 days post-treatment 
(day 15).  
 
2.4. Horizontal locomotor activity (HLA) measurement 
The animals were given their treatment (saline, MDPV or cocaine solutions) and 
immediately placed in a black Plexiglass open field arena (25 x 25 x 40 cm) under low-
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light conditions and white noise. HLA was video-monitored for 30 min using a specific 
tracking software (Smart 3.0 Panlab, Barcelona, Spain). All HLA experiments were 
performed during the resting-phase of the animals (between 8:00 am and 2:00 pm). 
 
2.5. Effects of 7,8-DHF on the development of behavioral sensitization after 
repeated exposure to cocaine or MDPV 
To evaluate the sensitizing effects of MDPV and cocaine under a previous treatment 
with 7,8-DHF, mice were assigned to one of the following four groups: vehicle + saline; 
vehicle + MDPV or cocaine; 7,8-DHF + saline and 7,8-DHF + MDPV or cocaine. 7,8-
DHF (10 mg/kg, i.p.) was administered 30 min prior to the saline or drug injection, to 
ensure constant levels of the agonist throughout all the procedure. The treatment 
schedule used was the same as in the cross-sensitization experiments, but the HLA 
was only recorded after the challenge with MDPV or cocaine, on day 15.  The 7,8-DHF 
dose as well as the administration schedule were selected according to those used in 
multiple studies in the literature [23,44]. 
 
2.6. Tissue sample preparations 
Mice treated according to the administration protocols described above were sacrificed 
by cervical dislocation, 1h or 2h after an acute dose and 2h, 24h or 10 days after the 
repeated regime, for the analysis of different factors including: G9a, BDNF and D3R. 
NAcc, ventral striatum (VS) containing NAcc, or medium prefrontal cortex (mPFC), 
when appropriate, were quickly dissected out and stored at -80ºC until use. 
Particularly, for the dissection of the NAcc and the mPFC, brains were rapidly removed 
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and placed in an ice-cold mouse brain acrylic matrix (Alto, Agnthos, Sweden). Two 
double edge blades were properly inserted to obtain a 2 mm (2 mm anterior to bregma) 
or 1 mm (from 2 to 3 mm anterior to bregma) thick slices, respectively, which contained 
the regions of interest [45]. The NAcc was micropunched away from the rest of the 
brain tissue. 
Tissue samples for ELISA analysis were processed following the instructions provided 
by the kit manufacturer. Briefly, NAcc samples were thawed and homogenized through 
sonication at 4°C in 100 volumes of RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
(v/v) NP-40 and 0.5% (w/v) sodium deoxycholate, pH=7,5-8) containing a protease 
and phosphatase inhibitor cocktail. Once homogenized, samples were kept on ice for 
30 min. Sample sonication and cooling with ice were performed twice. Homogenates 
were centrifuged at 14,000 x g for 30 min at 4ºC and the resulting supernatants (total 
lysates) were collected and kept at -80ºC until use. Protein content was determined 
using the Bio-Rad Protein Reagent (Bio Rad, Inc., Madrid, Spain). 
 
2.7. Quantification of mBDNF and proBDNF protein levels 
The determination of proBDNF and mBDNF was performed following the instructions 
of the corresponding ELISA kit. In brief, the kit consisted of a microplate pre-
coated with mouse monoclonal anti-mature or polyclonal anti-proBDNF capture 
antibodies. Then, samples containing unknown amount of the target protein were 
added and bound to the capture antibody. After washing steps to rid the microplate of 
unbound substances, a biotinylated anti-mature or anti-proBDNF detection antibody, 
respectively, and horseradish peroxidase (HRP)-conjugated streptavidin were added 
for detection. The addition of a substrate (3,3’,5,5’-tetramethylbenzidine, 
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TMB) yielded a colored reaction product that was directly proportional to the 
concentration of mature or proBDNF present in samples and protein standards.  
 
2.8. Total RNA extraction and gene expression determination 
Total RNA isolation from ventral striatum or mPFC was carried out by means of a 
TRIsureTM reagent-Chloroform based extraction protocol. TRIsureTM (Bioline, Meridian 
Bioscience Inc., UK), monophasic solution of phenol and guanidinium isothiocyanate, 
facilitates disruption of cells during homogenization and effectively inhibits DNase and 
RNase activity.  Simultaneously, solubilizes biological material and denatures protein. 
After solubilization, the addition of chloroform causes phase separation, where protein 
is extracted to the organic phase, DNA resolves at the interface, and RNA remains in 
the aqueous phase [46].  RNA content in the samples was measured at 260 nm, and 
sample purity was determined by the A260/280 ratio in a NanoDropTM ND-1000 
(Thermo Scientific). 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) was performed using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and the 
Veriti® thermal cycler (Applied Biosystems, Foster, CA, USA). Briefly, complementary 
DNA (cDNA) was synthesized in a total volume of 20 μL by mixing 1 μg of total RNA 
and the appropriate volumes of each kit reagent.  
Quantitative real-time polymerase chain reaction (qPCR) was performed using 
the StepOnePlusTM Real-Time PCR System and the Taqman one-step PCR Master 
Mix (Applied Biosystems, Foster, CA, USA). In brief, 25 ng of total cDNA was added 
per 20-µl reaction mixture containing sequence-specific primers and Taqman probes 
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from Applied Biosystems Mm0113261_m1 for G9a, Mm04230607_s1 for BDNF, 
Mm00432887_m1 for D3R and Mm00607939_s1 for β-actin. The β-actin transcript 
level was used to normalize differences in sample loading and preparation. The 
reaction conditions were as follows: the holding stage was initiated by a 2-min 
incubation at 50ºC and 10 min of polymerase activation at 95ºC, followed by a cycling 
stage of 40 cycles at 95ºC for 15 s and 60ºC for 60 s. All reactions were performed in 
triplicate. Fold-changes in gene expression were determined using the 2-ΔΔCt method 
(comparative Ct method) for each experimental sample [47] . All primer-probe 
combinations were optimized and validated for relative quantification of gene 
expression. All experiments included a no-template control, and real-time PCR 
reactions also included a no-reverse transcriptase (no-RT) control for which no 
amplification products were seen, indicating that cDNA was amplified rather than 
residual genomic DNA. 
 
2.9. Conditioned place preference (CPP) test 
The place conditioning protocol used was non-biased as described previously  [48] 
CPP was performed in three phases: preconditioning, conditioning and test. During the 
preconditioning phase (day 1), mice had free access and roam among the three 
compartments of the apparatus for 15 min. The time spent in each compartment was 
recorded by computerized monitoring software (Smart 3.0 Panlab, Barcelona, Spain). 
During the conditioning phase (days 2-5; sessions 1-8), mice were given 7,8-DHF (10 
mg/kg i.p.), 30 min before the s.c. administration of MDPV (1.5 mg/kg) or saline. After 
the MDPV injection, the animals were immediately placed into one of the two 
conditioning compartments for 20 min (sessions 1, 3, 5 and 7). On the alternate 
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sessions (2,4,6 and 8), mice were placed in the other compartment for 20 min after 
being given a saline injection. Two conditioning sessions per day were performed, 
separated by a 5-hours period. Control animals received saline every session. The 
preference test (day 6) was conducted as the preconditioning phase. A preference 
score was expressed in seconds and calculated for each animal as the difference 
between the time spent in the drug-paired compartment in the test minus the time spent 
in the same compartment in the preconditioning phase.  
 
2.10. Data acquisition and statistical analysis 
Data were expressed as mean ± SEM. Differences between groups were compared 
using one- or two-way ANOVA where appropriate. One-way ANOVA was used when 
analyzing differences due to the factor “treatment” in the experiment, whereas two-way 
ANOVA was performed when two different factors were analyzed: “treatment x time”. 
The α error probability was set at 0.05. Significant differences (P<0.05) were analyzed 
using the Tukey’s post hoc test for multiple comparisons measures where appropriate 
only if F achieved the necessary level of statistical significance (P<0.05) and no 
significant variance in homogeneity was observed. Every set of results was tested in 
the calculator QuickCalcs of GraphPad software, which performs Grubbs' test (extreme 
studentized deviate method), to determine whether any of the values in the set was a 
significant outlier from the rest. Statistic calculations were performed using GraphPAD 






3.1. Cross-sensitization between MDPV and cocaine 
To evaluate the ability of cocaine to sensitize to the motor stimulant effects of MDPV 
and vice versa, a bidirectional cross-sensitization experiment was performed following 
the administration regime displayed in Figure 1, in which two different doses of cocaine 
were tested (10 mg/kg and 15 mg/kg, i.p.). 
During the treatment phase, HLA was measured daily and immediately after each 
saline or drug injection. MDPV induced an acute hyperlocomotion that, unlike cocaine, 
significantly increased with repeated daily exposure (Figure 2). Accordingly, two-way 
ANOVA revealed an effect of the day (F4,368=8.681, P<0.001), treatment (F3,92=131.3,  
P<0.001) and the interaction between both factors (F12,368=1.931, P<0.05) 
(n=24/group). Moreover, MDPV-treated mice showed a significantly higher locomotor 
activity at a dose of 1.5 mg/kg during the treatment compared to cocaine at both doses 
tested (10 and 15 mg/kg).  
When analyzing the HLA after a challenge with MDPV (1 mg/kg, s.c.) or cocaine (8 
mg/kg i.p.) on day 15 after withdrawal (Figure 3A and 3B), a higher locomotor response 
was evidenced in both MDPV and cocaine-treated mice compared to the control group. 
Accordingly, one-way ANOVA reported an effect of treatment for both challenge drugs 
(MDPV challenge: F3,44=8.697, P<0.001, n=12/group; cocaine challenge: F3,43=14.15, 
P<0.001, saline, cocaine 15 mg/kg and MDPV-treated groups, n=12/group; cocaine 10 
mg/kg group, n=11). On the other hand, no differences were found between MDPV 
and cocaine-pretreated mice after the challenge with MDPV. However, it is noteworthy 
that, after the challenge with cocaine, MDPV-pretreated mice showed a higher 
locomotor response compared to cocaine 10 mg/kg-pretreated mice (P<0.05) but not 
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to those pretreated with cocaine 15 mg/kg. Therefore, repeated administration of 
cocaine 15 mg/kg or MDPV 1.5 mg/kg developed equivalent locomotor sensitization. 
Thus, the dose of 15 mg/kg of cocaine was chosen for the subsequent experiments. 
 
3.2. Effect of MDPV and cocaine on G9a methyltransferase, BDNF and D3R 
expression 
To further investigate the role of the BDNF-TrkB pathway in the development of 
behavioral sensitization, we assessed and compared the changes occurred in related 
genes after both an acute and a repeated exposure to MDPV and cocaine.  
 
3.2.1. After an acute dose of MDPV or cocaine 
G9a methyltransferase mRNA in VS was determined 1h and 2h post-injection. Two-
way ANOVA revealed an effect of treatment (F2,29=8.166, P<0.01) and time 
(F1,29=14.02, P<0.001) with interaction between both factors (F2,29=8,090, P<0.01) 
(Figure 4A). 1 hour after an acute dose of MDPV (1.5 mg/kg) or cocaine (15 mg/kg), 
the levels of G9a mRNA were similarly increased in cocaine (P<0.05) and MDPV 
(P<0.01)-treated mice compared to the saline group. However, this overexpression 
had rapidly declined at 2 hours. Nevertheless, this decline was more marked for the 
MPDV-treated mice than for those treated with cocaine, so significant differences were 
found between both groups at 2 hours (P<0.01) as well as among the MDPV-treated 
mice when comparing between the two time-points (P<0.001) (saline 1h and MDPV 1h 
groups, n=5/group, cocaine 1h, saline 2h and MDPV 2h groups, n=6/group; cocaine 
2h group, n=7). 
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In addition, when assessing the expression of the transferase in the mPFC 2h post-
injection, no changes were observed neither by MDPV nor by cocaine administration 
(saline group, n=5; cocaine and MDPV groups, n=7/group) (Figure 4B).  
In the same brain area, one-way ANOVA of bdnf mRNA levels 2h post-administration 
yielded a significant effect of treatment (F2,16=23.73, P<.001) (Figure 4C). Particularly, 
an acute MDPV injection induced a significant overexpression of this factor (P<0.001), 
whereas no changes by cocaine were observed (saline group, n=5; cocaine and MDPV 
groups, n=7/group). 
Since cortical BDNF controls D3R expression in the NAcc, the mRNA levels encoding  
this receptor were  also assessed 2h post-administration in VS (containing NAcc). 
Nevertheless, no changes in D3R mRNA levels were evidenced in this area (Figure 
4D) (saline group, n=6; cocaine and MDPV groups, n=7/group). 
 
3.2.2. After a repeated exposure to MDPV or cocaine  
G9a gene expression was determined 2h and 24h after the last drug injection. Maze 
et al [28] described the effect of repeated cocaine exposure on G9a expression in NAcc 
at 24h but, due that we did not find changes at this time point, we assessed its levels 
also at 2h after drug administration.  
As shown in Figure 5A, two-way ANOVA (n=6/group) reported a significant effect of 
treatment (F2,30=3.811, P<0.05), time (F1,30=28.60, P<0.001) and the interaction 
between both factors (F2,30=9.743, P<0.001). Particularly, repeated cocaine exposure 
upregulated G9a in VS 2h post-treatment (P<0.01), whereas MDPV did not alter 
significantly its expression. However, when measuring G9a mRNA 24h post-treatment, 
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no changes were observed for cocaine, pointing to a transient overexpression of the 
methyltransferase, which had returned to control values at 24h of withdrawal. 
Regarding MDPV, despite no effect was observed after two hours, a significant 
reduction of G9a expression over time was evidenced when comparing between both 
time-points (P<0.05).  
We did not detect any effect induced by MDPV or cocaine on G9a transcript in mPFC 
2h post-treatment (n=6/group) (Figure 5B). 
In parallel, BDNF and D3R gene expression were determined 2h post-treatment in 
mPFC and VS, respectively. One-way ANOVA (n=6/group) revealed a significant effect 
of treatment (F2,15=7.590, P<0.01). Repeated exposure to MDPV, but not to cocaine, 
increased BDNF expression (P<0.05) (Figure 5C). At the same time, a similar pattern 
of expression was observed for D3R, although the differences observed did not reach 
statistical significance (n=6/group) (Figure 5D).  
Given the fact that those fluctuations in the level of BDNF transcription after drug 
exposure may not necessarily affect overall protein expression, pro- and mBDNF 
protein levels were assessed in dissected tissue from NAcc. Such protein levels were 
determined 2h after-treatment, but also 24h and 10 days after the last administration 
of both substances. 
Despite the observed increment in bdnf gene transcription induced by MDPV in mPFC, 
neither MDPV nor cocaine treatment altered proBDNF levels in NAcc (n=6/group) 
(Figure 6A). 
Surprisingly, two-way ANOVA revealed a significant effect of time (F2,44=4.782, 
P<0.05) and treatment (F2,44=7.650, P<0.01) in mBDNF expression, although no 
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interaction between both factors was evidenced. Therefore, despite no differences 
were observed in propeptide levels, mBDNF was decreased shortly after a chronic 
MDPV exposure (P<0.05), even though its levels were restored after 10 days of 
withdrawal. In cocaine-treated-mice, no changes were observed at any of the time-
points assessed until 10 days of withdrawal (saline 2h and day 10, cocaine 2h and 
24h, MDPV 2h and day 10 groups, n=6/group; saline 24h and MDPV 24h groups, 
n=5/group; cocaine day 10 group, n=7) (Figure 6B).  
 
3.3. Effect of 7,8-DHF on the development of locomotor sensitization after repeated 
administration of MDPV or cocaine 
Given the decrease of mBDNF protein levels observed 2h after a chronic MDPV 
exposure, we sought to determine if this change was involved in the development of 
locomotor sensitization to the drug. To investigate this participation, 7,8-DHF, a TrkB 
receptor agonist, was administered 30 min prior to every drug injection (pretreatment). 
From the experiments with MDPV (Figure 7A), one-way ANOVA revealed a significant 
effect of treatment (F3,32 = 19,64, P<0.001) (n=8/group). As we expected, post-hoc 
analysis showed that exposure to MDPV (1.5 mg/kg) significantly increased 
(P<0.0001) acute MDPV (1 mg/kg)-induced locomotion 10 days after treatment, 
compared to its control group (vehicle + saline treated). Interestingly, pretreatment with 
7,8-DHF significantly blocked (P<0.001) such development of sensitization. Moreover, 
control (saline) animals pretreated with 7,8-DHF or the vehicle showed a similar 
locomotor response, which evidences the null effect of this agonist on the locomotor 
activity by itself.  
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To prove that the effect of 7,8-DHF in the development of locomotor sensitization to 
MDPV was mainly due to its ability to bind and selectively activate TrkB, ANA-12, an 
antagonist of this receptor, was administered previously to the flavone. One way- 
ANOVA, (F3,31 = 20.15, p<0.001) revealed that both groups exposed to MDPV (vehicle 
+ MDPV and ANA-12+7,8-DHF+MDPV) developed behavioral sensitization (25592 ± 
716, P<0.001 and 21343 ± 1192, P<0.01, respectively, vs saline-treated groups). This 
result suggested that ANA-12 prevented the binding of 7,8-DHF to TrkB and thereby 
its further activation, which seems to be involved in the effects induced by the agonist. 
No changes in the locomotor activity of control (saline) animals pretreated with ANA-
12 + 7,8-DHF were observed.  
On the other hand, in the experiments with cocaine, no effect of 7,8-DHF was 
evidenced in the development of behavioral sensitization (Figure 7B). One-way 
ANOVA (F3,42=16.33, P<0.001) evidenced that locomotor sensitization was similarly 
developed in both cocaine-treated groups, regardless they were pretreated or not with 
7,8-DHF. (“Vehicle + saline”, “7,8-DHF + saline”, “vehicle + cocaine” groups, 
n=12/group; “7,8-DHF + MDPV” group, n=10). 
 
3.4. Effect of 7,8-DHF on the place conditioning induced by MDPV 
The CPP paradigm was used to study whether 7,8-DHF could modify the conditioning 
properties of MDPV, aside from the development of locomotor sensitization.   
The percentages of time spent in both compartments during the preconditioning phase 
were 51.48 ± 2.45 % and 48.57 ± 2.45 % (p>0.05), indicating a total lack of preference 
for either side. 4 mice from the saline and MDPV groups were withdrawn from the 
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experiment due to an initial preference for one of the compartments (>65% of the total 
session time). One more animal from the MDPV group was withdrawn after the test 
day because it was a significant outlier (“Saline” and “7,8-DHF” groups, n=12/group; 
“MDPV” group, n=11 and “7,8-DHF + MDPV” group, n=13). 
On the test day (day 6, post-conditioning), one-way ANOVA revealed a significant 
effect of treatment (F3,44=16.50, P<0.001). Accordingly, the repeated administration of 
MDPV (1.5 mg/kg, s.c.) produced a preference for the MDPV-paired compartment 
(P<0.001) which was not modified by the previous administration of 7,8-DHF. 
Furthermore, 7,8-DHF did not exert any conditioning or aversive effect by itself (Figure 
8). 
 
4. DISCUSSION  
In a previous work, we reported that exposure of adolescent mice to MDPV sensitizes 
to cocaine effects and induces a higher vulnerability to cocaine abuse in adulthood 
[48]. Cocaine abuse represents a heavy burden of disease in many countries, 
becoming a global problem. Any factor that increases the vulnerability to cocaine 
abuse must be carefully evaluated. In this sense, the present study examines more 
closely the common pathways involved in the effects of MDPV and cocaine, using the 
same dose of MDPV previously described, and also mice at the beginning of 
periadolescence. Despite the risks associated with new cathinones use, little is known 
about their consequences, especially among adolescents, although the exposure 
pattern in this age group is very similar to that observed among adults [49].  
Based on their pharmacological mechanism, we tested the possible cross-sensitization 
between cocaine and MDPV. Following our schedule, during the induction of 
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sensitization, only MDPV elicited a hyperlocomotion that significantly increased with 
repeated daily exposure, whereas cocaine did not. Even so, regarding to the 
expression of sensitization (challenge day, 10 days after withdrawal), we observed that 
the induction of sensitization by cocaine 15 mg/kg was equivalent to that induced by 
MDPV 1.5 mg/kg. Additionally, our results demonstrate that repeated administration of 
MDPV or cocaine sensitizes to cocaine or MDPV locomotor effects, respectively.  
Moreover, this is the first time that it is evidenced that the challenge with MDPV triggers 
an enhanced locomotor activity in animals pretreated with cocaine. This is of chief 
significance since sensitization-like phenomena has been frequently proposed to 
account for relapses in drug consumption. In this line, here we demonstrate that 
previous consumption of one of these psychostimulants may favor relapse when a new 
dose is taken after a withdrawal period an also may favor the onset of an addiction to 
the other drug when taken for the first time.   
In previous studies [34,48] we found that, although repeated exposure to MDPV 
resulted in an increase in ΔFosB expression, as it occurs after cocaine exposure, other 
factors were not affected by this cathinone derivative. This suggested that additional 
pathways are involved in the MDPV effects. To gain more in-depth knowledge of these 
mechanisms, this study aimed to investigate the role of BDNF in the locomotor 
sensitization induced by MDPV and cocaine, as well as to assess the effects of a single 
administration of both psychostimulants in such signaling pathway.  
Dynamic alteration of BDNF expression and the consequent adjustments in brain 
functioning and neuronal plasticity are subjected to environmental changes (i.e., drug 
exposure) by means of altered epigenetic programming. Differential cocaine-induced 
effects at specific bdnf promoters are mediated by distinct epigenetic mechanisms. In 
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mammals, the trimethylation of histone H3 on lysine 9, which is catalyzed by the 
methylytransferase G9a, is commonly associated with gene silencing [50]. It has been 
described that there is an increase of G9a expression in NAcc after an acute dose of 
cocaine, but a decrease after repeated doses, which favors the expression of genes 
epigenetically controlled by this methyltransferase such as ∆FosB, BDNF or Arc [28].  
In the present study we found an early significant increase in G9a expression induced 
after an acute dose of cocaine or MDPV, which rapidly reverted. It is noteworthy that 
this decline was more marked for MDPV. However, when a schedule of repeated 
administrations was used, we also obtained an early very significant increase of G9a 
mRNA induced by cocaine, which disappeared 24 h after treatment. Again, the signal 
was more transient in the case of MDPV and, in fact, the early increase did not reach 
statistical significance. Taken together, we hypothesize that the initial increase might 
have taken place much earlier than when we performed the determination. 
Nevertheless, in a previous work from our lab [34], an overexpression of this 
transferase was observed in the VS 24h after a higher and longer MDPV exposure (1.5 
mg/kg, 2 doses in a day x 7 days). All over, our findings suggest that G9a expression 
after drug intake may be time and dose-dependent and, moreover, its regulation runs 
temporarily different for cocaine than for MDPV.   
BDNF gene is differentially regulated in regions of the mesolimbic pathway during the 
withdrawal or abstinence period following repeated cocaine administration [51]. 
Therefore, although the repressive role of G9 in the NAcc, no effect of this 
methyltransferase has been described in mPFC after cocaine exposure, but an 
increased histone acetylation [52]. In this sense, we considered it was worth to 
investigate if the changes in the methyltransferase transcription induced by these 
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psychostimulants were region-specific. G9a expression in mPFC was not altered 
neither by acute nor by repeated doses of both drugs, pointing that the changes in this 
histone methyltransferase produced by MDPV or cocaine administration occur only in 
the striatum, where probably play a relevant role in the regulation of behavioral 
responses to these DAT blockers [53].  
Considering the discrepancy observed in the epigenetic regulation according to the 
brain area (VS or mPFC), we determined the effect of cocaine and MDPV on bdnf 
transcription. Given the fact that Le Foll [54] described that a single exposure to  
cocaine (20 mg/kg) increases bdnf mRNA expression throughout the cortex in the adult 
rat, but not in the NAcc, we only determined bdnf expression in mPFC 2h after the 
injection of the psychostimulants. In our study, using adolescent mice and a lower dose 
of cocaine (15 mg/kg), we did not observe such increase in bdnf transcription. 
However, a clear difference between cocaine and MDPV equivalent treatments must 
be highlighted. A single dose of MDPV, but not of cocaine, was enough to upregulate 
BDNF mRNA levels, similarly to what had been reported after a semichronic treatment. 
Nevertheless, the G9a methyltransferase expression in the same brain area remained 
unaffected.  Hence, we can conclude that, shortly after an acute or repeated MDPV 
administration, BDNF mRNA expression in mPFC increases without being apparently 
under the control of G9a-mediated epigenetic mark.  
In adult mice, it has also been described a close relationship between increased BDNF 
mRNA expression in the cortex and an early increase of D3R mRNA in the NAcc [55]. 
In our study, using adolescent mice, even though MDPV generated an increase of the 
neurotrophin transcript, it did not cause any change in accumbal D3R mRNA, after 
acute or repeated exposure. 
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Based on the changes observed in mPFC, we decided to investigate BDNF protein in 
the NAcc. BDNF is initially synthesized as its precursor (proBDNF) and subsequently 
cleaved into mature BDNF (mBDNF), which can be anterogradely transported to its 
target neurons [56] In this sense, levels of both the pro (2h post-administration) and 
the mature isoforms (2h, 24h and 10 days after administration) of this protein (proBDNF 
and mBDNF, respectively) were determined. Despite the early increment observed in 
bdnf transcription induced by MDPV, neither MDPV nor cocaine treatment altered 
proBDNF protein levels in NAcc.  
We would like to emphasize once again the fact that alterations of G9a after repeated 
doses did not translate into any modification of the immature protein levels, so even 
though G9a is an important factor involved in cocaine-induced plasticity, it does not 
seem to exert a direct influence on the de novo synthesis of BDNF.  
Regarding cocaine, no effect on bdnf mRNA transcription, proBDNF or mBDNF protein 
levels were evidenced at any time until 10 days of withdrawal. These findings agree 
with the lack of changes in BDNF expression observed during early cocaine withdrawal 
[57,58]. In fact, changes only appear after 3 weeks- 30 days of withdrawal. On the 
other hand, the effects of cocaine in BDNF protein synthesis generate controversy. Li 
and Wolf  [15] summarized these effects in a long table in which only one of the 30 
cites referred to a study performed in mice [59]. Zhang and co-workers exposed 
C57BL/6J mice to 20 mg/kg cocaine for seven consecutive days. Under these 
conditions, BDNF expression was slightly induced in the NAcc and caudate putamen 
(CPu). The rest of the existing literature report the effects of cocaine on BDNF 
especially in rats, at doses greater than 15 mg/kg, and mainly after a long withdrawal. 
In contrast, the effects that the authors observed shortly after repeated cocaine doses 
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are controversial when examining BDNF mRNA and protein levels [20,57]. Overall, 
although cocaine exposure generally leads to increases in BDNF levels in reward-
related brain regions, exceptions have also been observed. So, the regional selectivity 
and timing of cocaine effects can vary widely depending on the experimental conditions 
[15].   
In the same way, we demonstrated that repeated MDPV administrations induced 
temporal and regional-specific changes in BDNF expression, with a decoupling 
between transcriptional and translational processes. Conversely to the discrete up-
regulation of mRNA levels in mPFC, mBDNF protein levels were reduced in the NAcc 
just after treatment, although they were restored after 10 days of withdrawal.  Fumagalli 
et al. [60] also described a decoupling between transcriptional and translational 
processes shortly after repeated cocaine exposure (five daily injections, 5mg/kg), 
which differently modulates BDNF mRNA in PFC and protein levels in rat striatum. 
Concretely, cocaine increased BDNF mRNA levels 2h after the last injection with no 
changes in mBDNF protein levels in the striatum. Moreover, it   has been described 
that BDNF protein levels in the NAcc progressively increase after withdrawal from 
cocaine self-administration, but this gradual increase does not derive from local protein 
synthesis in NAcc neurons [20,58].  
Considering these unexpected results, a new in vivo experiment was carried out in 
sought to determine if such decline in mBDNF levels induced by the cathinone was 
related to locomotor sensitization. Therefore, a new sensitization experiment was 
carried out, but in this case the animals were pretreated with 7,8-DHF, a BDNF 
receptor (TrkB) agonist. Daily administration of 7,8-DHF 30 minutes prior to the 
injection of MDPV during the induction period completely blocked the development of 
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sensitization to the cathinone. In addition, to prove that the effect of the flavone was 
exclusively mediated via TrkB activation, the same experiment was carried out in the 
presence of ANA-12, a potent and selective TrkB antagonist. ANA-12 prevented the 
effect of the flavone in such a way that the group ANA-12 + 7,8-DHF + MDPV 
developed locomotor sensitization after an MDPV challenge. 
Taken together, these results suggest that the decrease in mBDNF levels, and hence 
of its receptor stimulation, is involved in the sensitization developed to MDPV. In fact, 
the same effect of 7,8-DHF on the development of behavioral sensitization after 
repeated administration of methamphetamine (METH) was described by Ren et al. 
[23]. So, even though MDPV and methamphetamine have substantial differences 
regarding their mechanism of action, a decrease in BDNF protein levels has been 
found during early withdrawal of both substances [61]. Therefore, this suggests that 
METH and MDPV abusers may suffer from a severe dysfunction on BDNF-TrkB 
signaling, which is importantly involved in the development of behavioral sensitization. 
In fact, mouse models with reduced BDNF expression exhibit a variety of alterations in 
the DA system [62], which indicates that BDNF has some direct influence on this 
system.  
It is noteworthy that, regarding mBDNF levels, the differences between cocaine and 
MDPV observed in the in vitro determinations agree with the results of the in vivo 
experiments. So, the expression of cocaine-induced locomotor sensitization, for which 
no changes in mBDNF levels were observed, was not altered by the previous 
administration of the flavone. Therefore, other signaling pathways may be involved in 
the development of cocaine-induced sensitization despite the great similarity of its 
mechanism of action with that of MDPV. 
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Nevertheless, when assessing the rewarding properties of MDPV in the CPP 
paradigm, 7,8-DHF did not modify CPP acquisition, suggesting that the BDNF/BDNF-
TrkB modulation has a specific effect on the motor sensitization to the cathinone. In 
fact, behavioral sensitization and CPP have been proven to be modulated by different 
mechanisms. Associative memory develops correlation between drug-induced 
affective states and contextual cues, triggering craving and some goal-directed 
behavior toward drugs, like that seen in the CPP paradigm. However, the transition 
from recreational to pathological and compulsive drug seeking may involve associative 
(conditioned to the open field arena) and non-associative processes, such as 
sensitization, whereby the neural substrate mediating the response to the drug is 
directly augmented [62,63].  
In summary, repeated administration of MDPV or cocaine cross-sensitizes to their 
locomotor effects. When using equivalent sensitization doses of both 
psychostimulants, only MDPV induces early changes in BDNF transcription, and this 
ability to activate the mPFC and increase bdnf gene expression is preserved after a 
repeated treatment. However, although the cathinone increases cortical BDNF mRNA, 
the accumbal levels of the mature protein significantly decrease. Therefore,  exposure 
to psychostimulants does not always affect bdnf mRNA and protein expression in the 
same direction, possibly due to the complex regulation of BDNF synthesis and 
transport. Alternatively, upregulation of BDNF mRNA levels might be a compensatory 
response to the primary loss of mBDNF protein. Our findings demonstrate that BDNF, 
but not D3R plays a role in the development of MDPV-induced locomotor sensitization, 
which may influence susceptibility to drug abuse and drug relapse. Given the protective 
role of BDNF, we cannot rule out the possibility that neurons expressing lower levels 
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of BDNF after repeated MDPV injections could be more vulnerable because of reduced 
trophic support [64] . 
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LEGENDS FOR FIGURES 
Figure 1 
Drug administration protocol and experimental design. After two days of habituation 
(days -1 and 0), mice were treated with saline (5ml/kg), MDPV (1.5 mg/kg s.c.) or 
cocaine (10 mg/kg or 15 mg/kg i.p.), once daily for five consecutive days (days 1-5) 
and their horizontal locomotor activity was recorded. 10 days later (day 15), all mice 
were challenged with MDPV (1 mg/kg s.c.) or cocaine (8 mg/kg i.p.) and their HLA 
recorded. 
Figure 2 
Horizontal locomotor activity (30 min) induced by saline, cocaine (10 mg/kg or 15 
mg/kg, i.p.) and MDPV (1.5 mg/kg, s.c.) administration during the five days of 
treatment. Bars represent mean ± SEM of the distance travelled after each  injection. 
***P< 0.001 vs the saline-matched day. $P<0.05 and $$$P<0.001 vs the cocaine 10 
mg/kg-matched day. @@@P<0.001 vs the cocaine 15 mg/kg-matched day. ##P<0.01 
and ###P<0.001 vs MDPV day 1. 
Figure 3 
Effect of cocaine (10 mg/kg (Coc 10) or 15 mg/kg (Coc 15), i.p.) and MDPV (1.5 mg/kg 
(MDPV 1.5), s.c.) treatment on the horizontal locomotor activity (30 min) induced by 
MDPV (A) or cocaine (B). Bars represent mean ± SEM of the distance travelled after 
a single MDPV (1 mg/kg, s.c.) or cocaine (8 mg/kg, i.p.) injection 10 days after 




Effect of a single dose of MDPV (1.5 mg/kg, s.c.) or cocaine (15 mg/kg, i.p.) on the 
mRNA expression encoding G9a in VS 1h and 2h post-injection (A), G9a in mPFC 2h 
post-injection (B), BDNF in mPFC 2h post-injection (C), and D3R in VS 2h post-
injection (D). Results are expressed as mean ± SEM. *P<0.05, **P<0.01 and 
***P<0.001 vs saline group. #P<0.05 vs cocaine 2h. $$$ P<0.001 vs MDPV 1h. 
Figure 5 
Effect of MDPV (1.5 mg/kg, s.c.) and cocaine (15 mg/kg, i.p.) repeated exposure on 
the mRNA expression encoding G9a in VS 2h and 24h post-treatment (A), G9a in 
mPFC 2h post-treatment (B), BDNF in mPFC 2h post-treatment (C), and D3R in VS 
2h post-treatment (D). Results are expressed as mean ± SEM. *P<0.05 and **P<0.01 
vs saline group. $P<0.05 and $$$P<0.001 vs 2h-matched drug. 
Figure 6 
Effect of MDPV (1.5 mg/kg, s.c.) and cocaine (15 mg/kg, i.p.) repeated exposure on 
protein levels in NAcc of proBDNF 2h after exposure (A), and mBDNF 2h, 24h and 10 
days after the exposure (B). Results are expressed as mean ± SEM. *P<0.05 vs saline 
group. #P<0.05 vs MDPV. 
Figure 7 
Effect of 7,8-DHF (10 mg/kg, i.p.) pre-treatment on the development of locomotor 
sensitization to MDPV 1.5 mg/kg (A) or cocaine 15 mg/kg (B). Bars represent mean ± 
SEM of the distance travelled after an MDPV (1 mg/kg s.c.) or cocaine (8 mg/kg, i.p.) 
challenge 10 days after treatment. ***P<0.001 vs saline-treated groups. $$$P<0.001 




Effect of 7,8-DHF on MDPV (1.5 mg/kg s.c.)-induced conditioned place preference. 
The x-axis represents the treatment group, and the y-axis represents the preference 
score (difference between the time (s) spent in the drug-paired compartment on the 
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